Contact: 

dloynd@endurxpharm.com

EnduRx Pharmaceuticals Inc. 8340 N Thornydale Rd Suite 110-328, Tucson, AZ 85741 (855) 368-2878

EnduRx Pharmaceuticals is a wholly-owned subsidiary of OBDURO Biotechnologies

Development of a Novel Tumor-Targeting and Tumor-Penetrating Nanosystem for Breast Cancer Therapy

Sonke Svenson, PhD

Chief Scientific Officer

David Loynd

President & CEO

Steve Morris, MD

Chief Medical Officer

Funded by:

Department of Defense - Congressionally Directed Medical Research Programs

FY 19, Breast Cancer Research Program

Award W81XWH2010122 Amount $1,412,301.00

Principal Investigator: Stephan Morris

Press Release